Baird Downgrades Onyx Pharmaceuticals (ONXX) to Neutral; Nexavar Issues More Than Just Seasonality
Tweet Send to a Friend
Baird downgrades Onyx Pharmaceuticals (Nasdaq: ONXX) to Neutral.
Baird analyst says, "With important commercialvalue drivers now pushed out (Korea reimbursement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "With important commercialvalue drivers now pushed out (Korea reimbursement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
